Biocept, Inc.

Biocept, Inc. focuses on innovative liquid biopsy solutions for cancer detection and monitoring, enabling non-invasive diagnostics through advanced technology. Biocept, Inc. specializes in liquid biopsy solutions aimed at cancer diagnostics.

Founded in San Diego, US, the company raised USD 19 million through an IPO in February 2014, selling 1. 9 million shares at an exit price range of USD 10 to USD 12. The CEO, Michael Nall, leads the company, which has yet to report any significant pivots in strategy or operations. Biocept has completed 9 deals, with the most recent occurring on 2014-02-05, and has raised a total of USD 1.

00 mn. Biocept, Inc. specializes in the provision of innovative liquid biopsy solutions aimed at improving cancer detection and monitoring. Its core offerings include the Target Selector™ technology, which enables the extraction of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from blood samples.

This technology facilitates non-invasive cancer diagnostics, allowing healthcare professionals to obtain critical information about tumor characteristics and treatment responses without the need for traditional tissue biopsies. Biocept’s solutions are aimed at oncologists and laboratories, enhancing patient care through personalized treatment plans based on genetic insights. The company's products are distributed internationally, including North America, Europe, and parts of Asia, catering to hospitals, cancer treatment centers, and diagnostic laboratories. In the year 2022, Biocept generated revenue of USD 25.

86 mn with an EBITDA loss of USD 30. 33 mn. The company operates on a fee-for-service model, providing diagnostic testing services to healthcare institutions and oncologists, who pay for each test performed using Biocept's proprietary technology. Revenue is derived from both B2B transactions with healthcare facilities and direct transactions with end-users seeking diagnostic insights, with pricing reflecting the complexity and specificity of the tests offered.

Biocept plans to enhance its product offerings with new diagnostic tests designed to improve cancer management and patient outcomes. The company is targeting expansion into additional international markets, with specific focus on regions in Europe and Asia to be established by 2025. The funds raised through the IPO in February 2014 will be utilized to support these growth initiatives, enabling the development of new products while also expanding the company's market reach.